N
Nazia Mohammed
Researcher at Beatson West of Scotland Cancer Centre
Publications - 22
Citations - 629
Nazia Mohammed is an academic researcher from Beatson West of Scotland Cancer Centre. The author has contributed to research in topics: Lung cancer & Chemoradiotherapy. The author has an hindex of 8, co-authored 22 publications receiving 453 citations. Previous affiliations of Nazia Mohammed include Gartnavel General Hospital.
Papers
More filters
Journal ArticleDOI
Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens.
Journal ArticleDOI
Accelerated hypo-fractionated radiotherapy for non small cell lung cancer: results from 4 UK centres
O.S. Din,Susan Harden,Emma Hudson,Nazia Mohammed,Laura S Pemberton,Jason F. Lester,Debashis Biswas,L. Magee,Aisha Tufail,Ross Carruthers,Ghazia Sheikh,David Gilligan,Matthew Hatton +12 more
TL;DR: These data show respectable results for patients treated with accelerated hypo-fractionated radiotherapy for NSCLC with outcomes comparable to those reported for similar schedules and represent the largest published series to date for 55/20 regime.
Journal ArticleDOI
How public health services pay for radiotherapy in Europe: an ESTRO-HERO analysis of reimbursement.
Yolande Lievens,Yolande Lievens,Noémie Defourny,J. Corral,Chiara Gasparotto,Cai Grau,Josep M. Borràs,Elvisa Kozma,Felix Sedlmayer,Elena Slobina,Jean-François Daisne,Tatiana Hadjieva,Jiri Petera,Brian H Kristensen,Margit Valgma,Heikki Minn,Bruno Chauvet,Esther Gc Troost,Antonio Lopez Medina,Vassilis Kouloulias,Zoltan Takácsi-Nagy,Mary Coffey,Elvio Russi,Laimonas Jarusevicius,Michel Untereiner,Snezhana Smichkoska,Vanja Karadjinovic,Judith van Loon,Julian Malicki,Maria Lurdes Trigo,Ovidiu Coza,Tom Roques,Nazia Mohammed,Martin J. Rolles +33 more
TL;DR: Scientific societies and policy makers across Europe need to discuss new strategies for reimbursement, combining flexibility with incentives to improve productivity and quality, allowing radiation oncology services to follow evolving evidence.
Journal ArticleDOI
IDEAL-CRT: A Phase 1/2 Trial of Isotoxic Dose-Escalated Radiation Therapy and Concurrent Chemotherapy in Patients With Stage II/III Non-Small Cell Lung Cancer.
David Landau,Laura Hughes,Angela Baker,Andrew Bates,Michael Bayne,Nicholas Counsell,Angel Garcia-Alonso,Susan Harden,J. Hicks,Simon Hughes,Marianne Illsley,Iftekhar Khan,Virginia Laurence,Zafar Malik,Helen Mayles,William Philip M. Mayles,Elizabeth Miles,Nazia Mohammed,Yenting Ngai,E Parsons,James Spicer,Paula Wells,D. Wilkinson,John D. Fenwick +23 more
TL;DR: This article reported toxicity and early survival data for IDEAL-CRT, a trial of dose-escalated concurrent chemoradiotherapy (CRT) for non-small cell lung cancer.
Journal ArticleDOI
CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).
Corinne Faivre-Finn,Michael Snee,Linda Ashcroft,W. Appel,Fabrice Barlesi,Adityanarayan Bhatnagar,Andrea Bezjak,Felipe Cardenal,Pierre Fournel,Susan Harden,Cécile Le Péchoux,Rhona McMenemin,Nazia Mohammed,Mary O'Brien,Jason Pantarotto,Veerle Surmont,Jan P. van Meerbeeck,Penella J. Woll,Paul Lorigan,Fiona H Blackhall +19 more
TL;DR: The aim was to compare overall survival and toxicity of BD with OD RT using modern conformal RT techniques given concurrently with chemotherapy, and patients’ characteristics were well balanced in both arms.